TT
TwoStep Therapeutics
United States · Biotech
A peptide-targeting platform is advancing conjugate and radioligand therapies for solid tumors.
One targeting peptide, multiple therapy formats
TwoStep’s engineered polyspecific integrin-binding peptide, PIP, recognizes five tumor-associated integrins. Because these targets appear across many solid tumors and can vary within a tumor, PIP is designed to broaden tumor recognition beyond a therapy aimed at a single target.
The company links PIP to different treatment payloads: its lead peptide-drug conjugate TS-104 carries the cytotoxic drug MMAE, while the platform also supports radioligand therapies. TwoStep is advancing TS-104 through Phase 1 oncology development and building its pipeline; these are clinical-stage programs rather than marketed treatments.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A | $62.5M | 2048 Ventures — Role not disclosedInsight Partners — Role not disclosedMedical Excellence Capital — Role not disclosedM Ventures — Role not disclosedNFX — Role not disclosedPfizer Ventures — Role not disclosedStanford University — Role not disclosed |